Achievement of Target Blood Pressure Levels in Chronic Kidney Disease: A Salty Question?

American Journal of Kidney Diseases

Volumn 43, Issue 5, 2004, Pages 782-795

  De Nicola, Luca ^a   Minutolo, Roberto ^b   Bellizzi, Vincenzo ^b   Zoccali, Carmine ^b   Cianciaruso, Bruno ^b   Andreucci, Vittorio E ^b   Fuiano, Giorgio ^b   Conte, Giuseppe ^b  

^a Astrophysical Observatory of Capodimonte   (Italy)

^b NONE

Author keywords

Cardiovascular (CV) disease; Chronic kidney disease (CKD); Diuretics; Guidelines; Hypertension; Low salt diet

Indexed keywords

FUROSEMIDE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; METOLAZONE; MINOXIDIL; SODIUM CHLORIDE; TORASEMIDE;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; HYPERTENSION; HYPOTHESIS; HYPOVOLEMIA; MEDICAL SPECIALIST; META ANALYSIS; PATIENT COMPLIANCE; POPULATION; PROTEINURIA; REVIEW; RISK FACTOR; SIDE EFFECT; SODIUM RESTRICTION; SODIUM RETENTION; WEIGHT REDUCTION;

EID: 1942466547     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2004.01.009     Document Type: Review

References (125)

1. Zoccali C: Cardiorenal risk as a new frontier of nephrology: Research needs and areas for intervention. Nephrol Dial Transplant 17:S50-S54, 2002 (suppl 11)
2. Sesso H, Stampfer MJ, Rosner B, et al: Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in men. Hypertension 36:801-807, 2000
3. Psaty BM, Furberg CD, Kuller LH, et al: Association between blood pressure level and the risk of myocardial infarction, stroke and total mortality. The Cardiovascular Health Study. Arch Intern Med 161:1183-1192, 2001
4. Pastor-Barriuso R, Banegas JR, Damian J, Appel LJ, Guallar E: Systolic blood pressure, diastolic blood pressure and pulse pressure. An evaluation of their joint effect on mortality. Ann Intern Med 139:731-739, 2003
5. Lewington S, Clarke R, Qizilbash N, et al: Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903-1913, 2002
6. Chobanian AV, Bakris GL, Black HR, et al: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 42:1206-1252, 2003
7. Vasan RS, Larson MG, Leip EP, et al: Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345:1291-1297, 2001
8. Monsterd A, D'Agostino RB, Silbershatz H, et al: Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 340:1221-1227, 1999
9. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561-1566, 1990
10. Verdecchia P, Schillaci G, Borgioni C, et al: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97:48-54, 1998
11. Staessen JA, Wang JG, Thijs L: Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 318:1305-1315, 2001
12. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 288:2981-2997, 2002
13. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA 283:1967-1975, 2000
14. National Kidney Foundation Task Force on Cardiovascular Disease: Controlling the epidemic of cardiovascular disease in chronic renal failure. Am J Kidney Dis 32:S1-S199, 1998 (suppl 3)
15. Foley RN, Parfrey PS, Harnett JD, et al: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47:186-192, 1995
16. Shulman NB, Ford CE, Hall WD, et al: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-Up Program. Hypertension 13:I180-I193, 1989
17. Ruilope LM, Salvetti A, Jamerson K, et al: Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 12:218-225, 2001
18. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134:629-636, 2001
19. Manjunath G, Tighiouart H, Coresh J, et al: Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 63:1121-1129, 2003
20. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 56:2214-2219, 1999
21. Munter P, He J, Loria C, Whelton PK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13:745-753, 2002
22. Garg AX, Clark WF, Haynes RB, House AA: Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I. Kidney Int 61:1486-1494, 2002
23. Manjunath G, Tighiouart H, Ibrahim H, et al: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 41:47-55, 2003
24. Wright RS, Reeder GS, Herzog CA, et al: Acute myocardial infarction and renal dysfunction: A high-risk combination. Ann Intern Med 137:563-570, 2002
25. Sarnak MJ, Levey AS, Schoolwerth AC, et al: Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154-2169, 2003
26. Wannamethee SG, Shaper AG, Perry IJ: Serum creatinine concentration and risk of cardiovascular disease. Stroke 28:557-563, 1997
27. Henry RMA, Kostense PJ, Bos G, et al: Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoom study. Kidney Int 62:1402-1407, 2002
28. Schillaci G, Reboldi G, Verdecchia P: High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med 161:886-891, 2001
29. Pahor M, Shorr RI, Somes GW, et al: Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the Systolic Hypertension in the Elderly Program. Arch Intern Med 158:1340-1345, 1998
30. De Leeuw PW, Thijs L, Birkenhager WH, et al: Prognostic significance of renal function in elderly patients with isolated systolic hypertension. Results from the Syst-Eur Trial. J Am Soc Nephrol 13:2213-2222, 2002
31. Wang JG, Staessen JA, Fagard RH, Birkenhager WH, Gong L, Liu L, for the Syst-China Trial Collaborative Group: Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 37:1069-1074, 2001
32. Cerne D, Kaplan-Pavlovcic S, Kranjec I, Jurgens G: Mildly elevated serum creatinine concentration correlates with the extent of coronary atherosclerosis. Ren Fail 22:799-808, 2000
33. Gale CR, Ashurst H, Phillips NJ, Moat SJ, Bonham JR, Martyn CN: Renal function, plasma homocysteine and carotid atherosclerosis in elderly people. Atherosclerosis 154:141-146, 2001
34. Coresh J, Wei LG, McQuillan G, et al: Prevalence of high blood pressure and elevated serum creatinine level in the United States. Findings from the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 161:1207-1216, 2001
35. Lucas MF, Quereda C, Teruel JL, Orte L, Marcen R, Ortuno J: Effect of hypertension before beginning dialysis on survival of hemodialysis patients. Am J Kidney Dis 41:814-821, 2003
36. Buckalew VM, Berg RL, Wang S, Porush JG, Rauch S, Schulman G: Prevalence of hypertension in 1,795 subjects with chronic renal disease: The Modification of Diet in Renal Disease Study baseline cohort. Am J Kidney Dis 28:811-821, 1996
37. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27:347-354, 1996
38. Zoccali C, Benedetto FA, Mallamaci F, et al: Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 12:2768-2774, 2001
39. Levin A, Thompson CR, Ethir J, et al: Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 34:125-134, 1999
40. Landray MJ, Thambyrajah J, Mc Glynn FJ, et al: Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. Am J Kidney Dis 38:537-546, 2001
41. Roger SD, McMahon LP, Clarkson A, et al: Effects of early and late intervention with epoetin alfa on left ventricular mass among patients with chronic kidney disease (stage 3 or 4). Results of a randomized clinical trial. J Am Soc Nephrol 15:148-156, 2004
42. Klag MJ, Whelton PK, Randall BL, et al: Blood pressure and end-stage renal disease in men. N Engl J Med 334:13-18, 1996
43. Young JH, Klag MJ, Muntner P, Whyte JL, Pahor M, Coresh J: Blood pressure and decline in kidney function. Findings from the Systolic Hypertension in the Elderly Program (SHEP). J Am Soc Nephrol 13:2776-2782, 2002
44. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S: Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 41:1341-1345, 2003
45. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA: Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 294:1443-1447, 1987
46. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
47. Brazy PC, Stead WW, Fitzwilliam JF: Progression of renal insufficiency: Role of blood pressure. Kidney Int 35:670-674, 1989
48. Zucchelli P, Zuccalà A, Borghi M, et al: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42:452-458, 1992
49. Klahr S, Levey AS, Beck GJ, et al: The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 330:877-884, 1994
50. Wright JT, Bakris G, Greene T, et al: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288:2421-2431, 2002
51. Jafar TH, Stark PC, Schmid CH, et al: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 139:244-252, 2003
52. Bakris GL, Weir MR, Shanifar S, et al: Effects of blood pressure level on progression of diabetic nephropathy. Results from the RENAAL Study. Arch Intern Med 163:1555-1565, 2003
53. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61:1086-1097, 2002
54. Rahman M, Barzilay J, Batuman V, et al, for the ALLHAT Collaborative Research Group: Incidence of end stage renal disease and cardiovascular disease in high risk hypertensive patients with reduced glomerular filtration rate. J Am Soc Nephrol 14:674A, 2003 (abstr)
55. Herzog CA: How to manage the renal patient with coronary heart disease. The agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol 14:2556-2572, 2003
56. Palmer BF: Renal dysfunction complicating the treatment of hypertension. N Engl J Med 347:1256-1261, 2002
57. Apperloo AJ, de Zeuw D, de Jong PE: A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 51:793-797, 1997
58. Peterson JC, Adler S, Burkart JM, et al: Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 123:754-762, 1995
59. Ruggenenti P, Perna A, Remuzzi G, on behalf of the investigators of the GISEN Group: Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int 63:2254-2261, 2003
60. Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure: The Sixth Report of the Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446, 1997
61. Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology: Guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053, 2003
62. Locatelli F, Marcelli D, Alberi D, et al: Hypertension as a factor in chronic renal insufficiency progression. High Blood Press 3:175-184, 1994
63. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al: Achievement and safety of a low blood pressure goal in chronic renal disease. Hypertension 29:641-650, 1997
64. Wright JT, Agodoa L, Contreras G, et al: Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 162: 1636-1643, 2002
65. Schwenger V, Ritz E: Audit of antihypertensive treatment in patients with renal failure. Nephrol Dial Transplant 13:3091-3095, 1998
66. Tonelli M, Gill J, Pandeya S, Bohm C, Levin A, Kiberd BA: Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency. Nephrol Dial Transplant 17:1426-1433, 2002
67. Levey AS: Nondiabetic kidney disease. N Engl J Med 347:1505-1511, 2002
68. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
69. Brenner BM, Cooper ME, De Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
70. Bakris GL, Williams M, Dworkin L, et al: Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 36:646-661, 2000
71. Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States. JAMA 290:199-206, 2003
72. Blumberg A, Nelp WB, Hegstrom RM, Scrirbner BH: Extracellular volume in patients with chronic renal disease treated for hypertension by sodium restriction. Lancet 2:69-73, 1967
73. Vasavada N, Agarwal R: Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int 64:1772-1779, 2003
74. Koomans HA, Roose JC, Mees EJD, Delawi IMK: Sodium balance in renal failure: A comparison with normal subjects under extremes of sodium intake. Hypertension 7:714-721, 1985
75. Dorhout Mees EJ: Volaemia and blood pressure in renal failure: Have old truths been forgotten? Nephrol Dial Transplant 10:1297-1298, 1995
76. Cianciaruso B, Bellizzi V, Minutolo R, et al: Renal adaptation to dietary sodium restriction in moderate renal failure resulting from chronic glomerular disease. J Am Soc Nephrol 7:306-313, 1996
77. Konishi Y, Okada N, Okamura M, et al: Sodium sensitivity of blood pressure appearing before hypertension and related to histological damage in IgA nephropathy. Hypertension 38:81-85, 2001
78. De Nicola L, Bellizzi V, Cianciaruso B, et al: Pathophysiological role and diuretic efficacy of atrial natriuretic peptide in renal patients. J Am Soc Nephrol 8:445-455, 1997
79. Sorensen SS, Danielsen H, Pedersen EB: Increased atrial natriuretic peptide in an early stage of chronic glomerulonephritis. Scand J Lab Invest 48:347-355, 1988
80. Omvik P, Tarazi RC, Bravo EL: Regulation of sodium balance in hypertension. Hypertension 2:515-523, 1980
81. Seldin DW, Preisig PA, Alpem RJ: Regulation of proximal reabsorption by effective arterial blood volume. Semin Nephrol 11:212-219, 1991
82. Pettinger WA, Mitchell HC: Renin release, saralasin and the vasodilator-beta-blocker drug interaction in man. N Engl J Med 292:1214-1217, 1975
83. Linas SL, Nies AS: Minoxidil. Ann Intern Med 94:61-65, 1981
84. Mallamaci F, Leonardis D, Bellizzi V, Zoccali C: Does high salt intake cause hyperfiltration in patients with essential hypertension? J Hum Hypertens 10:157-161, 1996
85. Mimran A, Ribstein J, DuCailar G, Halimi JM: Hyperfiltration in lean essential hypertension. Contrib Nephrol 119:98-102, 1996
86. Cianciaruso B, Bellizzi V, Minutolo R, et al: Salt intake and renal outcome in patients with progressive renal disease. Miner Electrolyte Metab 24:296-301, 1998
87. Di Iorio BR, Minutolo R, De Nicola L, et al: Supplemented very low protein diet ameliorates responsiveness to erythropoietin in chronic renal failure. Kidney Int 64:1822-1828, 2003
88. Navis G, De Jong PE, Donker AJM, Van Der Hem GK, De Zeuw D: Moderate sodium restriction in hypertensive subjects: Renal effects of ACE-inhibition. Kidney Int 31:815-819, 1985
89. Bakris GL, Smith A: Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Arch Intern Med 125:201-204, 1996
90. Elliot P, Stamler J, Nichols R, Stamler R, Kasteloot H, Marmot M, for Intersalt Cooperative Research Group: Intersalt revisited: Further analysis of 24 hour sodium excretion and blood pressure within and across populations. BMJ 312:1249-1253, 1996
91. Cappuccio FP, Markandu ND, Carney C, Sagnella GA, MacGregor GA: Double-blind randomised trial of modest salt restriction in older people. Lancet 350:850-854, 1997
92. Appel LJ, Espeland MA, Easter L, Wilson AC, Folmar S, Lacy CR: Effects of reduced sodium intake on hypertension control in older individuals-Results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med 161:685-693, 2001
93. Midgley JP, Matthew AG, Greenwood CMT, Logan AG: Effect of reduced dietary sodium on blood pressure: A meta-analysis of randomized controlled trials. JAMA 275: 1590-1597, 1996
94. Sacks FM, Svetkey LP, Vollmer WM, et al: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 344:3-10, 2001
95. He FJ, MacGregor GA: How far should salt intake be reduced? Hypertension 42:1093-1099, 2003
96. Morimoto A, Uzu T, Fujii T, et al: Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 350:1734-1737, 1997
97. Tuomilehto J, Jousilahti P, Rastenyte D, et al: Urinary sodium excretion and cardiovascular mortality in Finland: A prospective study. Lancet 357:848-851, 2001
98. Schmieder RE, Messerli FH, Garavaglia GE, Nunez BD: Dietary salt intake: A determinant of cardiac involvement in essential hypertension. Circulation 78:951-956, 1988
99. Alderman MH, Cohen H, Madhavan S: Dietary sodium intake and mortality. The National Health and Nutrition Examination Survey (NHANES I). Lancet 351:781-785, 1998
100. Alderman MH, Madhavan S, Cohen H, Sealey JE, Laragh JH: Low urinary sodium is associated with greater risk of myocardial infarction among treated hypertensive men. Hypertension 25:1144-1152, 1995
101. Alderman MH: Dietary sodium and cardiovascular health in hypertensive patients. The case against universal sodium restriction. J Am Soc Nephrol 15:S47-S50, 2004 (suppl 1)
102. Cianciaruso B, Capuano A, D'Amaro E, et al: Dietary compliance to a low protein and phosphate diet in patients with renal failure. Kidney Int 27:173-176, 1989
103. Rose BD: Diuretics. Kidney Int 39:336-352, 1991
104. Wilcox CS: New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 13:798-805, 2002
105. Dal Canton A, Russo D, Gallo R, et al: Diuretic therapy in uremic patients. Kidney Int Suppl 17:S154-S156, 1985
106. Andreucci M, Russo D, Fuiano G, Minutolo R, Andreucci VE: Diuretics in renal failure. Miner Electrolyte Metab 25:32-38, 1999
107. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D: The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 13:1682-1685, 1998
108. O'Connor DT, Preston RA, Mitas JA, Frigon RP, Stone RA: Urinary kallikrein activity and renal vascular resistance in the antihypertensive response to thiazide diuretics. Hypertension 3:139-147, 1981
109. O'Connor DT: Response of the renal kallikreinkinin system, intravascular volume and renal hemodynamics to sodium restriction and diuretic treatment in essential hypertension. Hypertension 4:III72-III78, 1982
110. Bank N, Lief PD, Piczon O: Use of diuretics in treatment of hypertension secondary to renal disease. Arch Intern Med 138:1524-1529, 1978
111. Dal Canton A, Fuiano G, Conte G, et al: Mechanism of increased plasma urea after diuretic therapy in uraemic patients. Clin Sci 68:255-261, 1985
112. Vasavada N, Saha C, Agarwal R: A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. Kidney Int 64:632-640, 2003
113. Wollam GL, Tarazif RC, Bravo EL, Dustan HP: Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J Med 72:929-938, 1982
114. Fliser D, Schroter M, Neubeck M, Ritz E: Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 46:482-488, 1994
115. Minutolo R, Andreucci M, Balletta MM, Russo D: Effect of posture on sodium excretion and diuretic efficacy in nephrotic patients. Am J Kidney Dis 36:719-727, 2000
116. Wilcox CS, Mitch WE, Kelly RA, et al: Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med 102:450-458, 1983
117. Berlowitz DR, Ash AS, Hickey EC, et al: Inadequate management of blood pressure in a hypertensive population. N Engl J Med 339:1957-1963, 1998
118. Hyman DJ, Pavlik VN: Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 345:479-486, 2001
119. Oliveria SA, Lapuerta P, McCarthy BD, et al: Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 162:413-420, 2002
120. Borzecki AM, Wong AT, Hickey EC, Ash AS, Berlowitz DR: Hypertension control. How well are we doing? Arch Intern Med 163:2705-2711, 2003
121. Phillips LS, Branch WT Jr, Cook CB, et al: Clinical inertia. Ann Intern Med 135:825-834, 2001
122. Moser M: Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA 279:1813-1816, 1998
123. Maschio G: How good are nephrologists at controlling blood pressure in renal patients? Nephrol Dial Transplant 14:2075-2077, 1999
124. Danovitch GM, Bourgoignie J, Bricker NS: Reversibility of the salt-losing tendency of chronic renal failure. N Engl J Med 296:14-19, 1977
125. De Nicola L, Minutolo R, Zamboli P, et al, for the TABLE Study Group: Comprehensive audit of antihypertensive treatment in patients with chronic renal insufficiency. J Am Soc Nephrol 14:761A, 2003 (abstr)